Decreased Platelet Aggregation

DrugDrug NameDrug Indication
DB06209PrasugrelIndicated in combination with acetylsalicylic acid (ASA) to prevent atherothrombotic events in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI). May be used in patients with unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI) who are to be managed with PCI. Prasugrel is not recommended in patients 75 years of age or greater, those that weigh<60kg, and patients with a history of stroke or transient ischemic attack due to increased risk of fatal and intracranial bleeding.
DB00063EptifibatideFor treatment of myocardial infarction and acute coronary syndrome.
DB00775TirofibanFor treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.
DB00975DipyridamoleFor as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
DB00208TiclopidineUsed in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.
DB08816TicagrelorTicagrelor is indicated for the prevention of thrombotic events like stroke or heart attack in patients with acute coronary syndrome or myocardial infarction with ST elevation.
DB06441CangrelorFor use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
DB00758ClopidogrelFor the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease.
DB00945Acetylsalicylic acid**Pain, fever, and inflammation** Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures [FDA label]. The _extra strength_ formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound)[FDA label]. **Other indications** ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include: Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) [FDA label]. Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction [FDA label]. For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) [FDA label]. For the prevention of thromboembolism after hip replacement surgery [FDA label]. For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) [FDA label]. Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site [FDA Label]. **Important note regarding use of the extended-release formulation [F4405]** In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action [Label, F4405]. The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA [F4405].
DrugDrug NameTargetType
DB06209PrasugrelP2Y purinoceptor 12target
DB06209PrasugrelCocaine esteraseenzyme
DB06209PrasugrelCytochrome P450 3A4enzyme
DB06209PrasugrelCytochrome P450 2B6enzyme
DB06209PrasugrelCytochrome P450 2C9enzyme
DB06209PrasugrelCytochrome P450 2C19enzyme
DB06209PrasugrelSerum albumincarrier
DB00063EptifibatideIntegrin beta-3target
DB00775TirofibanIntegrin alpha-IIbtarget
DB00775TirofibanIntegrin beta-3target
DB00975DipyridamolecAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10Atarget
DB00975DipyridamolecGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00975DipyridamolecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB00975DipyridamoleAdenosine deaminasetarget
DB00975DipyridamoleMultidrug resistance-associated protein 4transporter
DB00975DipyridamoleMultidrug resistance-associated protein 5transporter
DB00975DipyridamoleMultidrug resistance protein 1transporter
DB00975DipyridamoleCalcipressin-1target
DB00975DipyridamoleAlpha-1-acid glycoprotein 1target
DB00975DipyridamoleSolute carrier organic anion transporter family member 1B1transporter
DB00975DipyridamoleSolute carrier organic anion transporter family member 1B3transporter
DB00975DipyridamoleSolute carrier organic anion transporter family member 2B1transporter
DB00975DipyridamoleBile salt export pumptransporter
DB00208TiclopidineP2Y purinoceptor 12target
DB00208TiclopidineCytochrome P450 3A4enzyme
DB00208TiclopidineCytochrome P450 2C19enzyme
DB00208TiclopidineCytochrome P450 2B6enzyme
DB00208TiclopidineCytochrome P450 2C9enzyme
DB00208TiclopidineCytochrome P450 2D6enzyme
DB00208TiclopidineMyeloperoxidaseenzyme
DB00208TiclopidineCytochrome P450 1A1enzyme
DB00208TiclopidineCytochrome P450 1A2enzyme
DB00208TiclopidineCytochrome P450 2C8enzyme
DB00208TiclopidineCytochrome P450 2E1enzyme
DB08816TicagrelorCytochrome P450 3A4enzyme
DB08816TicagrelorP2Y purinoceptor 12target
DB08816TicagrelorMultidrug resistance protein 1transporter
DB08816TicagrelorCytochrome P450 2D6enzyme
DB08816TicagrelorCytochrome P450 2C9enzyme
DB06441CangrelorP2Y purinoceptor 12target
DB00758ClopidogrelP2Y purinoceptor 12target
DB00758ClopidogrelCytochrome P450 3A4enzyme
DB00758ClopidogrelCytochrome P450 2B6enzyme
DB00758ClopidogrelCytochrome P450 3A5enzyme
DB00758ClopidogrelCytochrome P450 2C19enzyme
DB00758ClopidogrelCytochrome P450 2C9enzyme
DB00758ClopidogrelCytochrome P450 1A2enzyme
DB00758ClopidogrelCytochrome P450 2C8enzyme
DB00758ClopidogrelLiver carboxylesterase 1enzyme
DB00758ClopidogrelMultidrug resistance protein 1transporter
DB00758ClopidogrelSolute carrier family 22 member 1transporter
DB00758ClopidogrelSolute carrier family 22 member 2transporter
DB00945Acetylsalicylic acidProstaglandin G/H synthase 1target
DB00945Acetylsalicylic acidProstaglandin G/H synthase 2target
DB00945Acetylsalicylic acidAldo-keto reductase family 1 member C1target
DB00945Acetylsalicylic acidSolute carrier family 22 member 6transporter
DB00945Acetylsalicylic acidMultidrug resistance protein 1transporter
DB00945Acetylsalicylic acidCytochrome P450 2C19enzyme
DB00945Acetylsalicylic acidCytochrome P450 2C9enzyme
DB00945Acetylsalicylic acid5'-AMP-activated protein kinasetarget
DB00945Acetylsalicylic acidEndothelin-1 receptortarget
DB00945Acetylsalicylic acidNuclear factor kappa b beta subunittarget
DB00945Acetylsalicylic acidCellular tumor antigen p53target
DB00945Acetylsalicylic acid78 kDa glucose-regulated proteintarget
DB00945Acetylsalicylic acidRibosomal protein S6 kinase alpha-3target
DB00945Acetylsalicylic acidNF-kappa-B inhibitor alphatarget
DB00945Acetylsalicylic acidTumor necrosis factor-inducible gene 6 proteintarget
DB00945Acetylsalicylic acidCaspase-1target
DB00945Acetylsalicylic acidCaspase-3target
DB00945Acetylsalicylic acidInhibitor of nuclear factor kappa-B kinase subunit betatarget
DB00945Acetylsalicylic acidExtracellular signal-regulated kinase (ERK)target
DB00945Acetylsalicylic acidG1/S-specific cyclin-D1target
DB00945Acetylsalicylic acidMyc proto-oncogene proteintarget
DB00945Acetylsalicylic acidProliferating cell nuclear antigentarget
DB00945Acetylsalicylic acidCyclin Atarget
DB00945Acetylsalicylic acidUDP-glucuronosyltransferase 1-6enzyme
DB00945Acetylsalicylic acidArylamine N-acetyltransferase 2enzyme
DB00945Acetylsalicylic acidSolute carrier family 22 member 8transporter